New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence.
UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases.“Those who have never received a measles vaccine (MMR) are at risk,” said UKHSA.MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward.Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s (‘Wakefield cohorts’) and some may still not be fully vaccinated.As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with targeted outreach to groups in London.Data published today by the UK Health Security Agency (UKHSA) shows there has been a steady rise in measles cases this year. It shows, between 1 January and 30 June this year there have been 128 cases of measles, compared to 54 cases in the whole of 2022, with 66 per cent of the cases detected in London although cases have been seen in all regions.The UKHSA assessment finds the risk of a measles epidemic across the UK is considered low. However, with lower current levels of coverage in London, a measles outbreak of between 40,000 and 160,000 cases could occur in the capital.The assessment also concludes that there is a high risk of cases linked to overseas travel leading to outbreaks in specific population groups such as young people and under-vaccinated communities.The risk in London is primarily due to low vaccination rates over several years, further impacted by the COVID-19 pandemic, particularly in some areas and groups where coverage of the first MMR dose at 2 years of age is as low as 69.5%.NHS England has launched a targeted national campaign to encourage uptake of the MMR vaccine, including targeted outreach work in London for those identified as at high risk and communities with the lowest uptake of vaccination.Search
Latest Stories
Start your day right!
Get the latest updates and insights delivered to your inbox
Related News
More For You
HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life
Gettyimages
NICE approves twice-a-day tablet for advanced breast cancer
Apr 11, 2025
Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.
The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.
“We’re looking at capivasertib with fulvestrant for people whose cancer has come back or got worse after treatment with a type of drug called a CKD 4 and 6 inhibitor and an aromatase inhibitor, a type of hormone therapy,” NICE said.
Developed by AstraZeneca, capivasertib is a targeted treatment called a kinase inhibitor, and it works by “blocking the action of an abnormal protein that tells cancer cells to multiply”, helping slow or stop the spread of cancer cells.
Clinical trial results have shown that capivasertib plus fulvestrant can delay disease progression by approximately 4.2 months compared with placebo plus fulvestrant.
“People with advanced breast cancer would value treatments like capivasertib that can be given when limited options exist and because it may delay the need for chemotherapy and its associated side-effects,” said Helen Knight, director of medicines evaluation at NICE.
“We are therefore pleased the company has worked with us so that we are able to recommend this promising new treatment as a good use of NHS resources and value for money for taxpayers.”
NICE noted that although capivasertib plus fulvestrant has not been directly compared in a clinical trial with other recommended treatments like alpelisib plus fulvestrant and everolimus plus exemestane, indirect comparisons suggest it is likely to offer similar benefits.
HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life. But, outcomes appear to be worse if the cancer has alterations in the PIK3CA, AKT1 or PTEN genes.
With this decision, NICE has now approved 24 out of the 25 breast cancer treatments it has reviewed over the past seven years.
Keep ReadingShow less
Most Popular
Don’t Miss Out
Get the latest updates and insights delivered to your inbox.
The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.
Photo credit: gettyimages
Review of 2024 VPAG scheme to be completed by June
Apr 05, 2025
The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.
The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.
The 2024 Voluntary Scheme, which came into effect on 1 January 2024 following the expiry of the 2019 agreement, aims to support the affordability of branded medicines for the NHS, improve patient access to the latest lifesaving treatments and boost the UK’s position as a global leader in advanced healthcare, technology, and clinical research. It will remain in place until the end of 2028.
The deal included a planned review of scheme terms in the autumn of 2025 to allow the government and industry to propose and implement necessary changes to ensure the scheme is delivering on its objectives.
The review will focus on addressing concerns about the significantly higher than expected ‘headline payment rate’ for newer medicines in the scheme to restore its predictability and sustainability.
Richard Torbett, chief executive of the ABPI, welcomed the move, stating:“Wes Streeting has made clear his determination to work with our industry to address existing commercial challenges while also setting out a bold vision to transform the way the health system values medical innovation.”
“The first step is to address high and unpredictable medicine payment rates in June so we can then power forward to support the NHS 10-year plan and deliver the government's upcoming life sciences strategy.”
The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent, significantly higher than the industry had anticipated.
The association described the increase as “the highest-ever level” and warned that this would place “a very real strain on companies, which will not have factored this rate into their business plans for 2025.”
It highlighted that the industry will be required to pay around £3.4 billion to the government in 2025—more than the total payments made over the entire five-year VPAG scheme from 2014 to 2018.
Last month, the Department of Health and Social Care (DHSC) also proposed raising the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% in the second half of 2025, aiming to bring it in line with the VPAG headline rate.
The ABPI argued that rocketing payment rates are undermining government efforts to make life sciences a key pillar of its industrial strategy.
“The government has rightly identified life sciences as a critical growth sector for the economy, but unless these excessive payment rates under both the VPAG and Statutory Scheme are addressed, the UK will not see the growth and investment we all want,” said Torbett.
“We need an urgent ministerial commitment to work with industry to get the UK back to an internationally competitive position,” he added.
Both the Statutory Scheme and the VPAG regulate NHS spending on branded medicines.
Keep ReadingShow less
AAH upgrades ordering portal to improve product visibility
Apr 02, 2025
Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.
AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.
The portal, which can be used directly from a customer’s PMR, now features an upgraded online order pad for greater visibility and ease of use.
Additional optimisation tools have been incorporated to boost savings and increase availability when searching across suppliers.
Phil Maslin, senior commercial technology manager at AAH Pharmaceuticals, highlighted the benefits of the upgraded system:
“AAH Cascade allows customers to gain more control over their procurement. It saves time searching across multiple suppliers and provides clear, transparent pricing.”
“With the new digital features that have been added, customers can search, add and amend products within their online basket quickly and efficiently, and also easily view and order clinically equivalent products and alternative pack sizes.”
“Customers can then access detailed reports to help analyse and optimise their purchases.”
AAH Cascade is compatible with all PMR systems and integrates seamlessly with AAH Connect+, the wrap-around PMR solution from AAH, providing customers with industry-leading EMIS Proscript software, quality hardware, fast fibre broadband, preferential pricing and ongoing support and training.
The wholesaler delivers over 10 million items per week to more than 14,000 pharmacies and healthcare organisations across the UK, operating from 11 local distribution centres.
The company’s portfolio also includes its sister firms, Enterprise, a major wholesaler of health and beauty products serving over 4,000 pharmacies, and Trident Pharmaceuticals, a leading short-line supplier in the UK market.
Keep ReadingShow less
Skincare: One in five Brits go to bed without washing their face daily, survey finds
Apr 02, 2025
Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.
The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.
Despite this, individuals spend more on skincare products than on other personal care items, suggesting a disconnect between investment and usage.
Brits spend an average of £27 per month on skincare items, compared to £22 on hair care and £19 on oral health products.
When the respondents were asked to rank skincare products by importance, facial creams or moisturisers topped their list (42%), while facial serums (18%), toners (11%), exfoliators (11%), and face masks (10%) were deemed as less important.
Worryingly, only 15% ranked sunscreen/SPF as essential, highlighting a lack of awareness about its crucial role in reducing skin cancer risk.
Barriers to skincare commitment
The survey identified three most common factors limiting their time commitment to personal care – the cost of personal care products (30%), lack of motivation or energy (25%), and busy work schedules (23%).
Additionally, information overload and confusion may be preventing people from maintaining a consistent personal care routine.
In the survey, 20% of respondents stated that they felt overwhelmed by the volume of advice available and 12% felt pressured to maintain their routines, and 15% were unsure which products suit them best.
Kenvue's Northern Europe area managing director, Bas Vorsteveld, underscored the need for better education and practical solutions to help them achieve their skincare goals and maximise product benefits.
"Our survey highlights a critical insight: consumers are investing in the idea of better skin but struggling with the practices needed to achieve it,” he said.
Vorsteveld noted that everyday moments of care, such as a consistent skincare routine, are crucial for both physical and mental well-being.
“Educating consumers on the benefits of the products they use is essential to ensure their routines are effective and sustainable,” he added.
Generation Z leads in skincare dedication
The survey also found that the younger generation, particularly Generation Z (18-28 years), were more dedicated to skincare routines, spending nearly 20 minutes a day on them, compared to 15 minutes for Millennials (29-44 years) and 12 for Gen X (45-60 years).
Overall, Gen Z spends an impressive 58 minutes per day in their personal care routines, including skin and hair care and oral health - well above the national average of 40 minutes.
They cited hygiene (52%), the desire to look good (44%), and the overall health benefits (42%) as top reasons for prioritising personal care.
Moreover, 43% of Gen Z – more than any other generation - focus on personal care to boost their confidence.
Expert Advice on Building a Sustainable Routine
To provide expert insights, Kenvue partnered with renowned GP Dr. Punam Krishan, who emphasised the importance of a simple yet effective personal care regimen.
"Understanding the right personal care routine for your daily life is essential because consistency is key,” she said.
“It’s important to understand what your own body, skin or oral care needs are and find a routine and products that work for you. This can help to ensure that your personal care regimen is both effective and sustainable.”
She continued: “Some skincare essentials shouldn’t be forgotten, such as applying sunscreen daily to shield your skin from harmful UV rays.”
“Oral hygiene is equally important to avoid negative consequences such as plaque buildup, cavities, and gum disease.”
Besides maintaining good skin and hair care for daily hygiene, Dr. Krishan highlighted the importance of regular exercise in enhancing overall well-being and self-esteem.
“Finally, remember to seek advice from a healthcare professional if you need recommendations tailored to your personal needs,” she added.
The survey underscores the importance of improving skincare education and offering practical solutions to help consumers develop consistent and effective routines.
Keep ReadingShow less
Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.
gettyimages
Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA
Apr 01, 2025
The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.
Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.
Despite this boost, pharmacy bodies, including the Company Chemists’ Association (CCA), argue that the funding falls short of addressing the sector's financial pressures.
“Unfortunately, this contractual agreement does not meet the costs of delivering NHS community pharmacy services, so there is still the risk of further closures and service reductions,” a CCA spokesperson told Pharmacy Business.
“This is the first step in the right direction. However, given the findings of an economic independent review released on Friday, it is clear there is a still a significant gap between the cost of delivering NHS community pharmacy services and what pharmacies will be paid.”
The review found that the cost of providing NHS pharmaceutical services across England in 23/24 was £4.3-£5.7 billion.
Looking ahead, costs are projected to rise from £5.063 billion in 2023/24 to £8.106 billion by 2029/30.
With the agreed funding for 2025/26 set at £3.073 billion, there remains a shortfall of £1.99 billion.
“The community pharmacy sector remains in a fragile position as the gap between what it costs to deliver NHS community pharmacy services and what the sector receives is still significant,” the CCA spokesperson said, adding that they will continue working with the new government to attempt to bridge this gap.
NPA pauses collective action
Meanwhile, the National Pharmacy Association (NPA), which represents 6,000 independent community pharmacies in England, has decided to pause its planned "collective action" after receiving the government’s new pay deal.
The unprecedented action, which was set to begin today (April 1), would have seen community pharmacies stop providing some services and reduce opening hours – marking the first such "work to rule" protest in the NPA's 104-year history.
“We are currently taking soundings from NPA members and working through the financial numbers, before making decisions on our next steps – both in terms of political campaigning and practical support for members,” an NPA spokesperson told Pharmacy Business.
The NPA board will meet early next week to consider the fundamental question of “whether independent pharmacies now have a fair chance of surviving in the short term and thriving in the future.”
“The answer to that question will determine the shape of NPA strategy going forward,” the spokesperson added.
Health Minister Stephen Kinnock had previously described the planned collective action as “premature, unnecessary, and detrimental to community pharmacy patients,” urging the NPA to reconsider its stance and await the outcome of contract negotiations.
Announcing the record investment, Kinnock described the funding deal as “a vital first step to getting community pharmacies back on their feet and fit for the future.”
“The agreement shows how this government is working in partnership with community pharmacy to deliver more care for patients closer to their home, freeing up GP appointments, and catching ill-health earlier and preventing it in the first place,” he said.
Nearly 250 pharmacies closed in 2024 alone—an average of nearly five per week—according to data from the NHS Business Services Authority (NHS BSA).
As of the end of January 2025, the number of community pharmacies (excluding distance selling pharmacies) in England had fallen to 10,025—a loss of 812 since the start of 2021, when the total stood at 10,837.
Keep ReadingShow less
Load More
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc